

# ACTIVITIES AND AGENDA SUBCOMMITTEE

August 27, 1981

## MINUTES

The Activities and Agenda Subcommittee met on August 27, 1981, at 9:30 a.m., in Conference Room 8, Building 31C. Board members present were: Dr. Harold Amos, Chairman, Dr. Henry Pitot, Dr. Fred Seitz, Mr. Sheldon Samuels, and Mrs. Rose Kushner. NCI staff included: Mrs. Barbara Bynum, Executive Secretary, Dr. Richard D. Costlow, Mr. Paul Van Nevel, Lorraine Kershner, Dr. Saul A. Schepartz, Dr. Ihor Masnyk, Dr. Al Rabson, Dr. Mary A. Fink, Dr. William A. Walter, Dr. Richard Adamsom, and Mr. Philip Amoroso. Visitors included Jerry Boyd, of the Cancer Newsletter, and Peggy L. Young.

After opening the meeting, the Chairman considered dates for the next two Subcommittee meetings--Monday, November 30, 1981, at the close of NCAB business; and Thursday, April 1, 1982, were selected.

Items for consideration for inclusion on the October or November NCAB agendas were each then addressed in turn:

Items 1-3: (1) STUDY SECTION PRACTICE OF SELECTING FUNDABLE PARTS OF GRANT APPLICATIONS AND GIVING PRIORITIES ON THOSE PARTS. (2) GRANTS OF HIGH PROGRAM RELEVANCE THAT DO NOT DO WELL IN REVIEW. (3) FATE OF INTERESTING IDEAS THAT DO NOT FARE WELL IN REVIEW. Since these are all concerned with review, consideration was postponed until a later date when both the Panel and NCAB members will participate.

Item 4: CHANGING SOURCES OF PATIENTS FOR CLINICAL TRIALS. This will be incorporated in the presentations described in #15, in November.

Item 5: TOXICOLOGY STUDIES FOR FDA AND FOR DCT CLINICAL TRIALS. This will be presented at the October meeting, possibly by Dr. DeVita.

Item 6: PROS AND CONS OF ANIMAL MODELS. This will be presented at the October meeting, possibly by Dr. Raub.

Item 7: REGIONAL MEETINGS (FIELD HEARINGS)--The concept of holding regional NCAB meetings was reiterated by Mr. Samuels. Discussion of the pros and cons will be presented to the NCAB in October in Dr. Amos' committee report.

Extra Item: Dr. Katterhagen's idea for the formation of an NCAB "Sub-committee on Cancer Control and the Community" was discussed. Dr. Pitot suggested that an ad hoc committee be appointed now and a determination made later on the need for a permanent committee. Dr. Amos will present this to the full NCAB in his committee report.

Item 8: POLICY GUIDELINES FOR INVITING OUTSIDE SPEAKERS TO NCAB MEETINGS--The Activities and Agenda Subcommittee will review all requests; those in the best interests of the NCAB will be considered. The consensus was that rigid guidelines were a hindrance and are unnecessary.

Items 9-10: (9) CEILING ON TOTAL FUNDS FOR SINGLE P.I.'S (10) MERITS  
POI VS. ROI--These items will be discussed at the next NCI retreat and  
will be considered by the Activities and Agenda Subcommittee after  
that time.

Item 11: HOW TO GET NCAB MEMBERSHIP TO TAKE A MORE ACTIVE ROLE IN  
THE AGENDA--No longer necessary to consider.

Item 12: HUMAN HYBRIDOMAS--HENRY KAPLAN (OCTOBER)--Dr. Pitot will  
invite Dr. Kaplan to present his recent studies with human hybridomas  
at the October meeting.

Item 13: REVIEW OF JOINT STUDIES WITH THE FORMALDEHYDE INSTITUTE--  
To be presented at October meeting, possibly by Dr. Fraumeni.

Item 14: REVIEW OF RELATIONSHIPS AND SUPPORT OF IARC--Dr. Pitot will  
attend the next IARC meeting and will invite the newly elected Chairman  
to address the NCAB at the February 1982 meeting.

Item 15: Dr. Pitot has invited the Directors of the AACI and ACCC to  
address the NCAB in November. "Changing sources of patients for clinical  
trials" (item #4) will be included in these presentations.

Meeting adjourned at 12:15 p.m.